Have been positive results of a study of security, for the use of an extract herbal (COLD-FX) which is an extract of ginseng patented in North America, for the treatment of the grip ales states in Canadian children, as a new resource, the results appear in the Official Journal of the American Academy of Pediatrics.

The randomized clinical trial, double-blind, placebo-controlled was carried out in collaboration with the University of Alberta in Canada was designed to measure the security and tolerability of COLD-FX for the treatment of a cold and flu in children.

In states acute with three days of dose FX were well tolerated, without serious adverse events, or differences in adverse developments versus the placebo group, the investigation was also successfully to determine the effect allowing a proper planning statistics.

“We hope that this trial is seen as timely and beneficial, in an area of the investigation where there is a clear demonstrated need of products are safe and effective for the treatment of cold and flu in children, who suffer from these ailments much more than the people,” said Jacqueline shan Official Head of Science and director-general of Technologies of CV.

He added that, “These results are promising and support the development of a formulation for children”.

The company anticipates the launch a large scale in clinical studies next year of efficacy trials to continue to support the use of COLD-FX for the treatment of colds and flu in children.

Seventy-five children between the ages of three and 12 years were recruited in Edmonton, Canada for the study, which was carried out in the winter of 2005-2006.